1 Laboratory of Bacterial Pathogenicity, Faculty of Biological Sciences, University of Concepcion, Chacabuco s/n, Concepcion, Bio Bio 4030000, Chile.
2 Laboratory of Immunobiotechnology, Reference Centre for Lactobacilli (CERELA-CONICET), Tucuman 4000, Argentina.
Benef Microbes. 2018 Sep 18;9(5):829-841. doi: 10.3920/BM2018.0019. Epub 2018 May 25.
Helicobacter pylori infection is associated with important gastric pathologies. An aggressive proinflammatory immune response is generated in the gastric tissue infected with H. pylori, resulting in gastritis and a series of morphological changes that increase the susceptibility to cancer development. Probiotics could present an alternative solution to prevent or decrease H. pylori infection. Among them, the use of immunomodulatory lactic acid bacteria represents a promising option to reduce the severity of chronic inflammatory-mediated tissue damage and to improve protective immunity against H. pylori. We previously isolated Lactobacillus fermentum UCO-979C from human gastric tissue and demonstrated its capacity to reduce adhesion of H. pylori to human gastric epithelial cells (AGS cells). In this work, the ability of L. fermentum UCO-979C to modulate immune response in AGS cells and PMA phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 (human monocytic leukaemia) macrophages in response to H. pylori infection was evaluated. We demonstrated that the UCO-979C strain is able to differentially modulate the cytokine response of gastric epithelial cells and macrophages after H. pylori infection. Of note, L. fermentum UCO-979C was able to significantly reduce the production of inflammatory cytokines and chemokines in AGS and THP-1 cells as well as increase the levels of immunoregulatory cytokines, indicating a remarkable anti-inflammatory effect. These findings strongly support the probiotic potential of L. fermentum UCO-979C and provide evidence of its beneficial effects against the inflammatory damage induced by H. pylori infection. Although our findings should be proven in appropriate experiments in vivo, in both H. pylori infection animal models and human trials, the results of the present work provide a scientific rationale for the use of L. fermentum UCO-979C to prevent or reduce H. pylori-induced gastric inflammation in humans.
幽门螺杆菌感染与重要的胃部病理有关。在感染幽门螺杆菌的胃组织中，会产生强烈的促炎免疫反应，导致胃炎和一系列增加癌症发展易感性的形态变化。益生菌可能是预防或减少幽门螺杆菌感染的一种替代方法。其中，使用免疫调节乳酸杆菌代表了一种有前途的选择，可以减轻慢性炎症介导的组织损伤的严重程度，并改善对幽门螺杆菌的保护性免疫。我们之前从人类胃组织中分离出乳酸杆菌 UCO-979C，并证明其能够减少幽门螺杆菌对人胃上皮细胞（AGS 细胞）的黏附。在这项工作中，评估了 L. fermentum UCO-979C 调节 AGS 细胞和 PMA 佛波醇 12-肉豆蔻酸 13-醋酸盐（PMA）分化的 THP-1（人单核白血病）巨噬细胞对幽门螺杆菌感染的免疫反应的能力。我们证明，UCO-979C 菌株能够在幽门螺杆菌感染后差异调节胃上皮细胞和巨噬细胞的细胞因子反应。值得注意的是，L. fermentum UCO-979C 能够显著降低 AGS 和 THP-1 细胞中炎症细胞因子和趋化因子的产生，并增加免疫调节细胞因子的水平，表明具有显著的抗炎作用。这些发现强烈支持 L. fermentum UCO-979C 的益生菌潜力，并为其对幽门螺杆菌感染引起的炎症损伤的有益作用提供了证据。尽管我们的发现应该在适当的体内实验中得到证实，但在幽门螺杆菌感染动物模型和人类试验中，本工作的结果为使用 L. fermentum UCO-979C 预防或减少人类幽门螺杆菌引起的胃炎症提供了科学依据。
